MAPT, microtubule associated protein tau, 4137

N. diseases: 469; N. variants: 292
Disease: Cerebral atrophy ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease BEFREE The pathological hallmarks of the disease include extra-neuronal deposition of amyloid-β (Aβ) as plaques and intra-neuronal hyperphosphorylated tau protein as neurofibrillary tangles, which cause neurodegeneration and cerebral atrophy. 30902161 2019
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease BEFREE We have also developed a blood tau biomarker that correlates with a cognitive decline and also with neuroimaging determinations of brain atrophy. 31099321 2019
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease BEFREE Alzheimer's disease is characterized by cognitive alterations, cerebral atrophy and neuropathological lesions including neuronal loss, accumulation of misfolded and aggregated β-amyloid peptides (Aβ) and tau proteins. 31481130 2019
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 GeneticVariation disease BEFREE P301L is the tau mutation most frequently observed in patients with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) and this mouse model recapitulates the progressive development of glial and neurofibrillary tangles, and associated cerebral atrophy observed in patients. 29568692 2018
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease BEFREE AD is characterized by brain atrophy due to neuronal and synaptic loss, extracellular amyloid plaques composed of amyloid-beta peptide (A<i>β</i>), and neurofibrillary tangles of hyperphosphorylated tau protein. 30405709 2018
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease BEFREE Alzheimer's disease is characterized by aggregated β-amyloid and tau proteins, but the clinical presentations and patterns of brain atrophy vary substantially. 30086796 2018
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease BEFREE We aimed to explore the association between CSF T-tau and brain atrophy 1 year post-stroke. 28583116 2017
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease BEFREE Recent evidence suggests that the pathophysiology and neuropathology of Alzheimer's disease comprises more than amyloid accumulation, tau protein pathology and finally brain atrophy with dementia. 23519520 2013
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease BEFREE Increased concentrations of tau protein in the CSF and an increase in brain atrophy were detected 15 years before expected symptom onset. 22784036 2012
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease BEFREE The annual rate of whole brain atrophy in the MAPT subjects was 2.4% per year (95% confidence interval [CI] 1.9-2.8). 21753165 2011
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease BEFREE An excess of senile plaques (beta-amyloid protein) and neurofibrillary tangles (tau protein), ventricular enlargement, and cortical atrophy characterizes it. 16246446 2005
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease BEFREE A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. 8846237 1995
CUI: C0235946
Disease: Cerebral atrophy
Cerebral atrophy 		0.200 Biomarker disease HPO